HealthWeight Loss
Eli Lilly's Retatrutide: A Promising New Weight Loss Drug
Eli Lilly's next-generation drug, retatrutide, has demonstrated significant weight loss in a crucial late-stage trial for patients with obes...
22 days ago
HealthWeight Loss
Eli Lilly's Oral GLP-1 Orforglipron Shows Promising Weight Loss Results
10 months agoUS
Eli Lilly's investigational oral GLP-1 receptor agonist, orforglipron, has demonstrated compelling efficacy in Phase 3 trials for weight loss and A1C reduction in adults with obesity or overweight and type 2 diabetes. These results pave the way for global regulatory submissions and could redefine obesity treatment worldwide.
Key Insights
•
Orforglipron led to an average weight loss of 10.5% (22.9 lbs) at the highest dose (36 mg) in a 72-week trial (ATTAIN-2), compared to 2.2% (5.1 lbs) with placebo.
•
A1C levels were reduced by an average of 1.3% to 1.8% from a baseline of 8.1% across different doses of orforglipron.
•
75% of participants taking the highest dose of orforglipron achieved an A1C ≤6.5%, meeting the American Diabetes Association's definition of diabetes.
•
Orforglipron showed clinically meaningful benefits across key cardiovascular risk factors, including non-HDL cholesterol, systolic blood pressure, and triglycerides.
•
Why does this matter? Orforglipron offers a convenient, once-daily oral option for weight loss and diabetes management, potentially increasing accessibility and adherence compared to injectable GLP-1 medications. The availability of an oral GLP-1 could significantly expand treatment options for patients who prefer oral therapies without sacrificing clinical results. This could lead to better management of diabetes and obesity, reducing the risk of associated health complications.
In-Depth Analysis
Eli Lilly's orforglipron is a once-daily small molecule oral glucagon-like peptide-1 (GLP-1) receptor agonist. The Phase 3 ATTAIN-2 trial (NCT05872620) was a 72-week, randomized, double-blind, placebo-controlled study involving over 1,600 participants across multiple countries. Participants with a BMI ≥27.0 kg/m² and type 2 diabetes were treated with orforglipron (6 mg, 12 mg, or 36 mg) or placebo.
The study met its primary endpoint, demonstrating that orforglipron is superior to placebo in mean body weight change from baseline at 72 weeks. The treatment-regimen estimand also showed statistically significant improvements across primary and key secondary endpoints.
The most common adverse events associated with orforglipron were gastrointestinal-related (nausea, vomiting, diarrhea, constipation, and dyspepsia) and generally mild to moderate in severity. Discontinuation rates due to adverse events were comparable to placebo.
Orforglipron's success in Phase 3 trials has triggered global regulatory submissions, with potential approval and availability expected in the near future. Kenneth Custer, Ph.D., Lilly executive vice president, emphasized the urgency to meet the needs of patients and the potential for global scalability of this convenient oral treatment.
FAQs
•
Q: How does orforglipron work?
Orforglipron is an oral GLP-1 receptor agonist that helps regulate blood sugar levels and promote weight loss by mimicking the effects of the natural GLP-1 hormone.
•
Q: What are the potential side effects of orforglipron?
The most common side effects are gastrointestinal-related, such as nausea, vomiting, and diarrhea. These are generally mild to moderate in severity.
•
Q: Who is orforglipron suitable for?
Orforglipron is intended for adults with obesity or overweight and type 2 diabetes. Consult with a healthcare provider to determine if it is the right treatment option.
•
Q: When will orforglipron be available?
Eli Lilly is moving toward global regulatory submissions, and the drug could potentially be available in the near future pending approvals.
Key Takeaways
•
Orforglipron offers a promising new oral treatment option for weight loss and diabetes management.
•
The drug has demonstrated significant weight loss and A1C reduction in clinical trials.
•
Orforglipron may provide a more accessible and convenient alternative to injectable GLP-1 medications.
•
Be aware of the potential gastrointestinal side effects and discuss them with your healthcare provider.
Discussion
Do you think orforglipron will redefine obesity treatment? Let us know in the comments below!
Share this article with others who need to stay ahead of this trend!
Related Articles
HealthWeight Loss
Natural Ozempic Alternative Discovered by Stanford Scientists
A groundbreaking discovery by Stanford Medicine has identified a natural molecule, dubbed BRP, that mirrors the weight loss benefits of sema...
about 2 months ago
HealthWeight Loss
Jillian Michaels and Megyn Kelly Open Up About Their Health Journeys
Staying healthy involves consistent effort and the journey looks different for everyone. Jillian Michaels and Megyn Kelly have recently shar...
2 months ago
HealthWeight Loss
Wegovy Maker Challenges Weight-Loss Drug Copycats Amidst Telehealth Boom
The market for weight-loss drugs is heating up as Novo Nordisk, the maker of Wegovy, takes legal action against telehealth companies like Hi...
4 months ago
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer